AZD3199: A potent and selective β2 -adrenergic receptor agonist with rapid onset of action Source: Annual Congress 2011 - Models of disease and drug actions Year: 2011
In vitro pharmacological profile of CHF 5407, a potent, long-acting and selective muscarinic M3 receptor antagonistSource: Eur Respir J 2007; 30: Suppl. 51, 25s Year: 2007
In vivo potent and long-lasting bronchodilator activity of muscarinic M3 receptor antagonist CHF5407Source: Eur Respir J 2007; 30: Suppl. 51, 26s Year: 2007
GB001 is a potent, insurmountable DP2 antagonist with long receptor residence time and extended pharmacodynamic effects Source: Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma Year: 2020
A novel dual-agonist challenge model in guinea pigs for assessment of individual and combined muscarinics antagonists and b2 adrenoceptor agonists bronchodilator efficacy Source: Annual Congress 2011 - Models of disease and drug actions Year: 2011
AZD3199: A fast acting β2 -receptor agonist with a long duration of action Source: Annual Congress 2011 - Translational models of disease Year: 2011
Aclidinium bromide, a novel muscarinic receptor antagonist combining long residence at M3 receptors and rapid plasma clearance Source: Annual Congress 2007 - New drugs for COPD Year: 2007
PKA/cAMP-independent transactivation of glucocorticoid receptor by long acting β2 agonists Source: Eur Respir J 2006; 28: Suppl. 50, 103s Year: 2006
In vitro pharmacological characterization of the novel inhaled bronchodilator CHF6366 acting as dual muscarinic antagonist/ß2-agonist (MABA) Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017
Ligand independent activation of the glucocorticoid receptor by long acting β2 agonists Source: Eur Respir J 2004; 24: Suppl. 48, 317s Year: 2004
The novel dual D2 dopamine receptor, β2 -adrenoceptor agonist Viozan™ (AR-C68397AA) is well tolerated in a dog model Source: Eur Respir J 2001; 18: Suppl. 33, 406s Year: 2001
Safety and toleration of pf-00610355, a novel inhaled long acting β2 adrenoreceptor agonist Source: Annual Congress 2009 - New bronchodilators Year: 2009
Unique receptor dissociation kinetics of the novel endothelin receptor antagonist macitentan Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012
The non-prostanoid IP receptor agonist, APD811 (ralinepag) has potent antiproliferative and vasorelaxant properties in human pulmonary artery Source: International Congress 2017 – Experimental PH Year: 2017
The novel dual D2 dopamine receptor, β2 -adrenoceptor agonist, Viozan™ (AR-C68397AA) improves quality of life and perception of efficacy Source: Eur Respir J 2001; 18: Suppl. 33, 3s Year: 2001
Pharmacological profile of a novel, potent and oral TRPA1 antagonist. Characterization in a preclinical model of induced cough Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015
The in vitro biology of PF-00610355 – a novel β2 adrenoceptor agonist with a long duration of action Source: Annual Congress 2009 - Models of chronic airways disease and therapy Year: 2009
Anti-inflammatory properties of synthetic and endogenous Rev-Erb-alpha agonists. Source: Virtual Congress 2020 – Asthma science: novel targets and mechanisms Year: 2020
Role of transient receptor potential vanilloid 4 in the therapeutic antifibrotic effects of pirfenidone Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia Year: 2019
Pharmacological activities of R-113281, a triple NK1 /NK2 /NK3 neurokinin receptor antagonist Source: Eur Respir J 2001; 18: Suppl. 33, 264s Year: 2001